AnaptysBio (NASDAQ:ANAB – Get Free Report) announced its earnings results on Monday. The biotechnology company reported $5.11 EPS for the quarter, topping the consensus estimate of ($0.46) by $5.57, FiscalAI reports. The company had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million.
AnaptysBio Trading Down 0.5%
NASDAQ ANAB traded down $0.28 during trading hours on Monday, hitting $54.92. 523,822 shares of the company’s stock were exchanged, compared to its average volume of 695,746. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -50.85 and a beta of 0.71. The stock has a 50-day simple moving average of $56.14 and a 200 day simple moving average of $59.25. AnaptysBio has a 1-year low of $13.66 and a 1-year high of $72.36.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on ANAB shares. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. TD Cowen decreased their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. Wolfe Research restated an “outperform” rating and issued a $78.00 price target on shares of AnaptysBio in a research report on Monday, August 31st. Finally, Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a research note on Tuesday, August 25th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $79.85.
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.
AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.
Further Reading
- Five stocks we like better than AnaptysBio
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
